Hepta

Detect, Monitor, And Enable Effective Treatment for Metabolic Disease

A liquid biopsy-native AI that interprets epigenetic patterns from blood to reveal liver biology Designed to enable non-invasive detection in routine care, starting with metabolic dysfunction-associated steatohepatitis (MASH)

Learn More!

Why It Matters

Early answers for those who need them most

Metabolic dysfunction-associated steatohepatitis (MASH) is a common chronic disease, affecting more than 20 million Americans, yet largely invisible in routine practice. Therapies exist, but diagnostics lag, so most patients are not found in time. Left undetected, MASH can progress to cirrhosis, organ failure, and cancer.

Current diagnostics pathways do not scale: Biopsy is invasive. Specialized imaging is scarce. Legacy blood scores often misclassify, leading to delayed diagnosis and preventable harm.

The liver is the body’s metabolic command center. Clinical practice needs a simple, trustworthy blood test that brings tissue-level insight into care early so clinicians can act before damage becomes irreversible.

Our Solution

A new way to decode liver biology from blood

Hepta is building the next generation liquid biopsy for MASH. From a standard blood draw, our platform interprets epigenetic patterns in cell-free DNA to reveal liver biology. It is non-invasive and designed for routine practice.

The technology pairs genomics with advanced AI to decode liver biology from blood, giving clinicians a clear way to identify patients earlier and guide next steps before irreversible damage to the body.

Effects:

Multiple-fold broader and more equitable access to diagnostic testing for clinicians and patients
Earlier treatment for eligible patients, before irreversible progression

Platform Vision

Building a blood-based foundation for chronic disease care

A blood-based window on tissue biology supports early detection, treatment decisions, and longitudinal monitoring.

Hepta reads molecular signals of liver inflammation and fibrosis from blood with its liquid biopsy-native AI. The same architecture is designed to help clinicians identify patients earlier, match biology to therapy, and follow molecular change over time.

We are focused first on MASH. As evidence grows, the platform is designed to extend to other serious chronic diseases driven by similar biology.

Who We AreOur team has helped shape modern liquid biopsy and advanced machine learning for genomic data. Hepta pairs that experience with leading hepatology expertise to build our AI-native liquid biopsy platform for MASH.

Leadership